The firm is an Asia-based venture capital investor managing multiple USD-denominated funds backed by institutional investors, including academic and healthcare organizations. The firm invests across the full company development spectrum, from Seed through Pre-IPO, and maintains flexibility in investment stage and financing structure. The firm is particularly interested in opportunities with a meaningful connection to China, including companies with Asian founders, cross-border development strategies, or commercial potential in Asian markets.
The firm invests across therapeutics, AI-enabled drug discovery, diagnostics, medical imaging, and other technologies at the intersection of artificial intelligence and healthcare. Within therapeutics, the firm has a particular interest in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is broadly indication-agnostic but prioritizes therapeutic areas with substantial market potential, including oncology, immunology, central nervous system disorders, pain management, and kidney diseases. The firm generally prefers therapeutic programs from IND-enabling development through clinical stages, although earlier opportunities may be considered beginning at the preclinical candidate selection stage.
From a company and management team perspective, the firm seeks differentiated technologies with strong scientific foundations, compelling commercial potential, and opportunities for cross-border growth. The firm places significant emphasis on management team quality and prefers leadership teams with relevant pharmaceutical or biotechnology industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
